Literature DB >> 11102423

Expression of the carbapenemase gene (cfiA) in Bacteroides fragilis.

R Edwards1, P N Read.   

Abstract

Bacteroides fragilis strains were studied to examine carbapenemase gene (cfiA) expression and insertion sequence (IS) element promoters. High-level resistance was associated with high meropenemase activity and IS elements upstream of cfiA. Sequencing revealed two element types; IS1187 and elements related to IS942 and IS1170. The latter was implicated in the conversion to carbapenem resistance in a cfiA-positive isolate during imipenem therapy. Two strains showing low-level resistance, and strains susceptible to meropenem, did not possess IS elements upstream of cfiA. The prevalence in Nottingham of clinical isolates of B. fragilis with cfiA and efficient IS element promoters was low (0.6%).

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11102423     DOI： 10.1093/jac/46.6.1009

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  10 in total

1.  Cross-infection due to imipenem-resistant Bacteroides fragilis associated with a totally implantable venous port.

Authors:  Corinne Arpin; Véronique Dubois; Anne-Marie Rogues; Fanny Menard; Anne-Marie Gavinet; Jean-Pierre Maire; Jean-Pierre Gachie; Marie-Christine Bezian; Claudine Quentin
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

Review 2.  Modes and modulations of antibiotic resistance gene expression.

Authors:  Florence Depardieu; Isabelle Podglajen; Roland Leclercq; Ekkehard Collatz; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Authors:  Hannah M Wexler; Adrian E Engel; Daniel Glass; Calida Li
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Differentiation of cfiA-negative and cfiA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Ingrid Wybo; Annelies De Bel; Oriane Soetens; Fedoua Echahidi; Kristof Vandoorslaer; Marina Van Cauwenbergh; Denis Piérard
Journal:  J Clin Microbiol       Date:  2011-02-23       Impact factor: 5.948

5.  In vitro activities of faropenem against 579 strains of anaerobic bacteria.

Authors:  Hannah M Wexler; Denise Molitoris; Shahera St John; Ann Vu; Erik K Read; Sydney M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Multiple mobile promoter regions for the rare carbapenem resistance gene of Bacteroides fragilis.

Authors:  I Podglajen; J Breuil; A Rohaut; C Monsempes; E Collatz
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

7.  Development and Validation of a Novel Anaerobic Carbapenem Inactivation Method (Ana-CIM) for the Detection of Carbapenemase Production in Bacteroides fragilis.

Authors:  Allison R Eberly; Meghan A Wallace; Samantha Shannon; Angela K Heitman; Audrey N Schuetz; Carey-Ann D Burnham; Sophonie Jean
Journal:  J Clin Microbiol       Date:  2022-03-22       Impact factor: 11.677

8.  Identification and characterization of conjugative transposons CTn86 and CTn9343 in Bacteroides fragilis strains.

Authors:  Simy L Buckwold; Nadja B Shoemaker; Cynthia L Sears; Augusto A Franco
Journal:  Appl Environ Microbiol       Date:  2006-10-27       Impact factor: 4.792

Review 9.  Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik's Cube of Clinical Microbiology?

Authors:  Márió Gajdács; Gabriella Spengler; Edit Urbán
Journal:  Antibiotics (Basel)       Date:  2017-11-07

10.  Prevalence and antimicrobial susceptibility of enterotoxigenic extra-intestinal Bacteroides fragilis among 13-year collection of isolates in Kuwait.

Authors:  Wafaa Jamal; Fatima Bibi Khodakhast; Ameerah AlAzmi; Jόzsef Sόki; Ghayda AlHashem; Vincent O Rotimi
Journal:  BMC Microbiol       Date:  2020-01-15       Impact factor: 3.605
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.